A Phase III, Multicenter, Open-Label, Extension Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigational eFlow® Device plus Standard of Care in the Treatment

  • Nandavaram, Sravanthi (PI)
  • Baz, Maher (Former PI)
  • Sekela, Michael (Former PI)

Grants and Contracts Details

StatusFinished
Effective start/end date6/30/20 → 3/20/24

Funding

  • Covance (foreign): $50,295.00